Vivos Therapeutics, Inc. (VVOS) stock forecast & analysis
0.1960
NasdaqCM · USD
Down: -0.0289, -12.9%
1 analysis
- Open
- 0.3976
- Previous close
- 0.2249
- Day range
- 0.1668 – 0.4559
- 52-week range
- 0.1668 – 4.63
- Volume (shares)
- 528.81M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 20.12M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 6.09
- Market cap
- 3.94M
Market Scanner’s AI analysis of Vivos Therapeutics, Inc. (VVOS), updated September 2026: Vivos Therapeutics' recent analyses covered revenue growth and strategic partnerships against a backdrop of technical downtrends and liquidity concerns.
Summary
Vivos Therapeutics' recent analyses covered revenue growth and strategic partnerships against a backdrop of technical downtrends and liquidity concerns.
Recent analyses for Vivos Therapeutics (VVOS) examined positive year-over-year quarterly revenue growth and strategic initiatives, including conference participation and new partnerships aimed at expanding service offerings. The reports also noted a record number of new patient referrals. However, the analyses also highlighted significant technical downtrends, negative short-term momentum, and liquidity challenges.
VVOS news & sentiment
News reports highlighted Vivos Therapeutics' strategic partnerships and expansion in service offerings, alongside a record number of new patient referrals. Social media discussion focused on the company's recent stock performance and technical downtrends.
VVOS technical picture
The technical indicators for VVOS presented a bearish outlook, with the price trading significantly below its 50-day and 200-day SMAs, indicating a strong downtrend. Momentum readings were negative, though the Money Flow Index suggested extremely strong buying pressure, hinting at a potential reversal.
Fundamentals
Vivos Therapeutics (VVOS) demonstrated positive year-over-year quarterly revenue growth, though trailing twelve months revenue was $20.902 million. The company remains unprofitable with negative profit, operating, and return on equity margins, and faces liquidity challenges indicated by low current and quick ratios.
Factors discussed — upside
- Positive year-over-year quarterly revenue growth of 34.9%
- Announced participation in the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
- Entered into definitive agreements with South Palm Cardiovascular Associates to establish a regional sleep testing and treatment center
- Reported a record number of new patient referrals at its Nevada Sleep & Airway Medicine Centers
- Extremely strong buying pressure indicated by MFI of 95.58
Factors discussed — risks
- Technical indicators present a bearish outlook with price significantly below 50-day and 200-day SMAs
- Steep decline in 7-day, 30-day, and 91-day price changes
- Short-term momentum is negative, with 10-day EMA below current price
- Company is currently unprofitable with negative profit and operating margins
- Liquidity challenges indicated by current ratio of 0.207 and quick ratio of 0.158
- Revenue growth
- Strategic partnerships
- Technical indicators
- Liquidity
Summary updated .
VVOS technical indicators
Common technical indicators for VVOS, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.38 | Price below |
| 10-day exponential moving average | 0.26 | Price below |
| Relative strength index (14-day) | 26.50 | Oversold |
| MACD line (12/26/9) | -0.0482 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 0.19 – 0.40 | Price inside the bands |
Analyses
Recent VVOS.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Vivos Therapeutics, Inc.?
- Recent analyses highlighted positive year-over-year quarterly revenue growth and strategic initiatives, including conference participation and new partnerships aimed at expanding service offerings, alongside a record number of new patient referrals.
- What are the risks for Vivos Therapeutics, Inc.?
- The analyses noted significant technical downtrends with the stock price well below key moving averages, steep short-term price declines, and negative momentum. Additionally, the company faces profitability challenges with negative margins and significant net losses, coupled with liquidity concerns indicated by low current and quick ratios.
- Is Vivos Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of Vivos Therapeutics, Inc. examined factors on both sides. Discussed upside: Recent analyses highlighted positive year-over-year quarterly revenue growth and strategic initiatives, including conference participation and new partnerships aimed at expanding service offerings, alongside a record number of new patient referrals. Discussed risks: The analyses noted significant technical downtrends with the stock price well below key moving averages, steep short-term price declines, and negative momentum. Additionally, the company faces profitability challenges with negative margins and significant net losses, coupled with liquidity concerns indicated by low current and quick ratios. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Vivos Therapeutics, Inc.?
- News reports highlighted Vivos Therapeutics' strategic partnerships and expansion in service offerings, alongside a record number of new patient referrals. Social media discussion focused on the company's recent stock performance and technical downtrends.
- Bundles used
- gemini-low-v2
Run a fresh VVOS.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every VVOS.US report already in the library